Whats new
Whats new.
CLSA - ESMO 2024-HNSCC presentation highlights favourable trends in efti + Keytruda; Rated Outperform, A$0.95 PT (Analyst: Andrew Paine)
September 15th 2024
For a copy of this research report please contact your CLSA advisor
Whats new
September 15th 2024
For a copy of this research report please contact your CLSA advisor